Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800CW fluorescence-guided surgery for cutaneous squamous cell carcinoma
NL-OMON49316Phase 1Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW in cutaneous squamous cell carcinoma (cSCC) and cutaneous malignancy, sponsored by University Medical Center Groningen. Primary endpoints: Macroscopic fluorescent signal and tracer distribution, Fluorescence quantification by spectroscopy and 1 more. Started Jul 2019; status: active, not recruiting.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
cutaneous squamous cell carcinoma (cSCC)cutaneous malignancy
Beyond the preview
Go deeper on NL-OMON49316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49316.